Efficacy and safety of DFN-11 (sumatriptan injection, 3  mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study

ConclusionsThis study met its primary endpoint, pain freedom at 2  h postdose, with DFN-11 significantly better than placebo, and the incidence of TEAEs and triptan sensations with DFN-11 was low. The 3 mg dose of sumatriptan in DFN-11 appears to be an effective alternative to a 6 mg SC dose of sumatriptan, with good safety and tolerability. (clinicaltrials.gov: NCT02569853; registered 07 October 2015).

Source: The Journal of Headache and Pain - August 15, 2018 Category: Neurology Source Type: research